Sponsor:
University of Manitoba
Code:
NCT04496817
Conditions
Diabetic Retinopathy
Type 2 Diabetes
Eligibility Criteria
Sex: All
Age: 19+
Healthy Volunteers: Accepted
Interventions
Docosahexaenoic Acid and Lutein Enriched Eggs
Regular Eggs
Brief summary:
Conditions
Diabetic Retinopathy
Type 2 Diabetes
Study ID
NCT04496817
Start date
Jul 11, 2022
Status verified date
Nov, 2023
Completion date
Sep 1, 2024
Anticipated
Primary completion date
Sep 1, 2024
Anticipated
Eligibility Criteria
Sex: All
Age: 19+
Healthy Volunteers: Accepted
Enrollment
60 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Prevention
Arms
experimental: Enriched Egg Group
placebo comparator: Regular Egg Group
Interventions
Docosahexaenoic Acid and Lutein Enriched Eggs
Regular Eggs
Primary outcome measure
Central contacts
Locations
Asper Clinical Research Institute
Recruiting
Winnipeg, Manitoba, Canada, R2H 2A6
Contacts
Sponsor
University of Manitoba
Last update posted
Nov 2, 2023
Last verified
Nov, 2023
Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-03. This information was provided to ClinicalTrials.gov by University of Manitoba on 2023-11-02. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.